H. Lundbeck AS Class A HLUN A
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- DKK 59.60
- Day Range
- DKK 56.50–62.00
- 52-Week Range
- DKK 31.40–62.00
- Bid/Ask
- DKK 56.70 / DKK 57.00
- Shares Outstanding
- 992.40M
- Market Cap
- DKK 56.47B
- Volume/Avg
- 174,477 / 125,010
Key Statistics
- Price/Earnings (Normalized)
- 9.20
- Price/Sales
- 2.15
- Dividend Yield (Trailing)
- 2.02%
- Dividend Yield (Forward)
- 2.02%
- Dividend Payment Schedule
- Mar
- Total Yield
- 2.06%
Company Profile
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Value
- Total Number of Employees
- 5,000
- Website
- https://www.lundbeck.com
Competitors
Valuation
Metric | HLUN A | ALNY |
|---|---|---|
Price/Earnings (Normalized) | 9.20 | 7.89 |
Price/Book Value | 2.00 | 5.94 |
Price/Sales | 2.15 | 4.39 |
Price/Cash Flow | 8.86 | 15.68 |
Price/Earnings
HLUN A
ALNY
Financial Strength
Metric | HLUN A | ALNY |
|---|---|---|
Quick Ratio | 0.99 | 2.26 |
Current Ratio | 1.43 | 2.48 |
Interest Coverage | — | 3.22 |
Quick Ratio
HLUN A
ALNY
Profitability
Metric | HLUN A | ALNY |
|---|---|---|
Return on Assets (Normalized) | 11.93% | 50.54% |
Return on Equity (Normalized) | 24.09% | 204.12% |
Return on Invested Capital (Normalized) | 16.48% | 112.35% |
Return on Assets
HLUN A
ALNY
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|!FbtVW! | LOCK|Hzn$v | $74B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|?>$sb#@ | LOCK|%@Y$ | $50B | |||
| Haleon PLC ADR HLN | LOCK|wHn^sSr | LOCK|f@S | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|N%<XdF^ | LOCK|PG | $34B | |||
| Viatris Inc VTRS | LOCK|qZRbJR! | LOCK|^gh | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|c@f | LOCK|Y<$ | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|m@xDYgj | LOCK|g^> | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|#^cjX! | LOCK|&M# | $5B | |||
| Perrigo Co PLC PRGO | LOCK|!<^vVY | LOCK|dy | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|Cr?M$? | LOCK|>qKTq | $2B |
United States